Many studies have demonstrated that bortezomib prevented IκBα from degradation by proteasome, thus inhibiting nuclear translocation of NF-κB, cytokine circuits and the survival advantage for MM cells conferred by the BM microenvironment [6, 34, 41]. Here, NFKB1 is linked to Miyoshi myopathy.